Pallas Capital Advisors LLC Invests $307,000 in Zimmer Biomet Holdings, Inc. $ZBH

Pallas Capital Advisors LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,361 shares of the medical equipment provider’s stock, valued at approximately $307,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Garde Capital Inc. purchased a new position in Zimmer Biomet in the first quarter valued at about $29,000. Menard Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at about $30,000. Washington Trust Advisors Inc. purchased a new position in Zimmer Biomet in the first quarter valued at about $30,000. Columbia River Financial Group LLC purchased a new position in Zimmer Biomet in the first quarter valued at about $30,000. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet during the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $100.03 on Monday. The stock has a fifty day moving average price of $100.06 and a two-hundred day moving average price of $99.35. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm has a market cap of $19.82 billion, a P/E ratio of 24.34, a PEG ratio of 2.30 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday. Stifel Nicolaus increased their price target on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday. Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 8th. Rothschild & Co Redburn started coverage on Zimmer Biomet in a research report on Thursday. They issued a “buy” rating and a $130.00 target price on the stock. Finally, Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $113.16.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.